Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating BMS-986523 alone and in combination with anti-cancer agents in advanced solid malignancies, including non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BMS-986523

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: RECRUITING